131614Small-molecule agonists of GLP-1R for the treatment of Type-2 diabetesClosedFeasibility StudiesInnovate UKType-2 diabetes has assumed almost epidemic proportions, resulting in a significant financial burden to healthcare systems in developed countries. GLP-1R agonism represents one of the mainstays of therapy for type-2 diabetes, but existing GLP-1 mimetics necessitate injection and have been associated with severe side effects. Through the use of its proprietary NMR-based approach to drug design, C4X Discovery (C4X) has built the first comprehensive pharmacophore GLP-1R agonist 'map' and used this to derive the smallest orthosteric agonist of GLP-1R so far reported. As part of the project, C4X will explore whether this molecule can form the basis of a chemical optimisation programme that will enable the creation of orally-available and cheaper alternatives to exisiting therapies, thereby providing a significant healthcare benefit in terms of increased patient convenience, improved compliance and reduced economic burden.